Results 51 to 60 of about 4,524 (132)
American Journal of Hematology, Volume 101, Issue 9, Page 2463-2468, September 2026.
Rodrigo Ortega Perez +19 more
wiley +1 more source
Autoimmunity and peginterferon therapy for polycythemia vera
HemaSphere, Volume 10, Issue 7, July 2026.Abstract Peginterferon‑α is useful to treat myeloproliferative neoplasms (MPNs) but can precipitate broad autoimmunity. By promoting beta‐cell, thyroid, and systemic immune injury, it can lead to Type 1 diabetes, autoimmune thyroiditis, systemic lupus erythematosus, or Sjögren's syndrome.
Etienne Rivière +8 more
wiley +1 more source
Journal of Hematology & Oncology, 2011 Background JAK2V617F is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs) and has become a valuable marker for diagnosis of MPNs.
Ho Wanting T +7 more
doaj +1 more source
Клиническая онкогематология, 2020 The publication contains materials of the reports presented at the II Conference “Current Issues of Diagnosis and Treatment of Ph-Negative and Ph-Positive Myeloproliferative Neoplasms” held from 15 to 16 March 2019 at the National Research Center for ...
A. L. Melikyan +50 more
doaj +1 more source
Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation
ACR Open Rheumatology, Volume 8, Issue 6, June 2026.Chronic inflammation, characteristic of many autoimmune diseases, such as rheumatoid arthritis (RA), or myeloproliferative neoplasms (MPNs), is an independent driver of accelerated cardiovascular (CV) risk, primarily through proinflammatory cytokines that induce atherosclerosis and endothelial dysfunction.
Aliki Zavoriti, Pierre Miossec
wiley +1 more source
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines
Experimental Hematology & Oncology, 2012 Background JAK2V617F, a gain-of-function mutant form of tyrosine kinase JAK2, is found in the majority of patients with Ph- myeloproliferative neoplasms (MPNs), a group of chronic hematological diseases that often lead to acute leukemia.
Zhao Wanke +4 more
doaj +1 more source
HematologyObjectives The aim of this study was to characterize the clinical features and outcomes of patients with JAK2 V617F- and CALR-unmutated essential thrombocythemia (ET) and to identify potential driver mutations through whole-exome sequencing (WES).Methods
Siraphop Thammayot +13 more
doaj +1 more source
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms
Mediators of Inflammation, 2015 The recent JAK1/2 inhibitor trial in myeloproliferative neoplasms (MPNs) showed that reducing inflammation can be more beneficial than targeting gene mutants.
Vladan P. Čokić +10 more
doaj +1 more source
Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation
Leukemia Research Reports, 2018 JAK2V617F mutation is found in about 60% of cases of essential thrombocytemia (ET) and represents a driving mutation. Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet (PLT) count.
Giovanni Caocci +3 more
doaj +1 more source
Haematologica, 2019 Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera is difficult because of shared mutation and phenotypic characteristics. The World Health Organization suggested hemoglobin and hematocrit values to diagnose polycythemia vera (PV),
Richard T. Silver, Spencer Krichevsky
doaj +1 more source